title: Successive double high-dose chemotherapy with peripheral blood stem cell rescue collected during a single leukapheresis round in patients with high-risk pediatric solid tumors: a pilot study in a single center.
abstract: In total, 18 of 26 double high-dose chemotherapies (HDCT) in pediatric solid tumors were rescued with peripheral blood stem cells collected during a single leukapheresis round (single-harvest group, SHG). In the remaining eight HDCT, additional leukapheresis were necessary after the first HDCT (HDCT1) to rescue the second HDCT (HDCT2) (double-harvest group, DHG). Stem cell collection after HDCT1 was inefficient and delayed in patients who had received prior chemotherapy before HDCT1. The interval between HDCT1 and HDCT2 was shorter in SHG than in DHG (median 62.5 days vs 178.5 days, P-value=0.002). Hematologic recovery in HDCT2 was delayed compared to HDCT1. However, there was no difference in hematologic recovery between SHG and DHG. A high rate of treatment-related mortality (TRM) was recorded during HDCT2, but there was no evidence that the shorter interval caused a higher rate of TRM (P-value=0.454). The probability of disease-free survival at 2 years after HDCT2 in the SHG and DHG were 66.7 and 25.0%, respectively (P-value=0.031). Therefore, to administer the second HDCT earlier in double HDCT, and thus to improve the survival of patients with high-risk solid tumors, the single-harvest approach is recommended rather than the double-harvest approach.
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: K W
authors.initials: KW
authors.lastname: Sung
authors.forename: K H
authors.initials: KH
authors.lastname: Yoo
authors.forename: E H
authors.initials: EH
authors.lastname: Chung
authors.forename: H L
authors.initials: HL
authors.lastname: Jung
authors.forename: H H
authors.initials: HH
authors.lastname: Koo
authors.forename: H J
authors.initials: HJ
authors.lastname: Shin
authors.forename: S K
authors.initials: SK
authors.lastname: Lee
authors.forename: D H
authors.initials: DH
authors.lastname: Lim
authors.forename: D W
authors.initials: DW
authors.lastname: Kim
authors.forename: H K
authors.initials: HK
authors.lastname: Park
authors.forename: E J
authors.initials: EJ
authors.lastname: Cho
authors.forename: S W
authors.initials: SW
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001792:Blood Platelets / Q000166:cytology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality; D002528:Cerebellar Neoplasms / Q000188:drug therapy / Q000401:mortality; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007937:Leukapheresis; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy / Q000401:mortality; D008875:Middle Aged; D009423:Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009447:Neuroblastoma / Q000188:drug therapy* / Q000401:mortality; D012307:Risk Factors; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents